Envestnet Portfolio Solutions Inc. Purchases 713 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Envestnet Portfolio Solutions Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,684 shares of the biopharmaceutical company’s stock after buying an additional 713 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,912,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Choate Investment Advisors grew its stake in shares of Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Choate Investment Advisors now owns 551 shares of the biopharmaceutical company’s stock valued at $392,000 after buying an additional 37 shares in the last quarter. Greykasell Wealth Strategies Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $504,000. Intact Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $356,000. Finally, Atala Financial Inc bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $154,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. TD Cowen decreased their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $662.62 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a fifty day moving average price of $690.20 and a two-hundred day moving average price of $821.82. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm has a market capitalization of $72.44 billion, a P/E ratio of 17.31, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company posted $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.